Micro Pharmaceuticals
Market Cap
₹1,599 ₹1,599 Cr.
P/E
35.16
PEG
2.17
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The thesis comes alive if organic growth, medical-representative productivity and Equitas integration progress broadly on schedule, with hospital cross-selling adding to the core branded-pharma engine.- The bull path requires faster hospital cross-selling, stronger representative productivity and new-product conversion; the bear path reflects integration delays, weaker organic growth and productivity shortfalls.

Key Ratios

Market cap
Market cap
1,599 Cr
PE
PE
35.16
Prom Holding
Prom Holding
69.05 %
ROE (%)
ROE (%)
15.60
ROCE (%)
ROCE (%)
21.02
Div Yield (%)
Div Yield (%)
2.28
Sales
Sales
293 Cr
OPM (%)
OPM (%)
20.79 %
Debt to Equity
Debt to Equity
-
Institutions
Institutions
2.92 %
Individual < 2 lac
Individual < 2 lac
15.95 %
No. of Shareholders
No. of Shareholders
24,181

About

Jagsonpal Pharmaceutical, a leading Indian company established in 1964, is focused on the deve… Read more
Low
155
52W Range
High
265
  • Jagsonpal Pharma
  • Lincoln Pharma
  • Syncom Formulations

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

Edit rows

Forensics

13 Yes

Positive for this company

2 Neutral

Neutral for this company

2 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Jagsonpal Pharmaceuticals Ltd. Business

Jagsonpal Pharmaceutical, founded in 1964, specializes in research, development, manufacturing, and distribution of bulk drugs and pharmaceutical formulations globally, aiming to establish a strong presence in the industry.

Jagsonpal Pharma major competitors are Lincoln Pharma, Syncom Formulations, Bharat Parenterals, Sakar Healthcare, Venus Remedies, Wanbury, Panacea Biotec.
Market Cap of Jagsonpal Pharma is ₹1,599 Crs.
While the median market cap of its peers are ₹2,032 Crs.

Jagsonpal Pharma seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material